Skip to main content
. 2019 Mar 24;8(3):408. doi: 10.3390/jcm8030408

Figure A3.

Figure A3

Epigenetic histone marks differ between control and YM155 treated human synovial sarcoma cells, HS-SY-II, at the BIRC5 promoter. ChIP-qPCR for H3K27me3 shows elevated levels at the BIRC5 promoter in the YM155 treated samples compared to controls. ChIP-qPCR for H3K27ac shows elevated levels at the BIRC5 promoter in the YM155 treated samples compared to controls. ChIP-qPCR for H3K4me1 shows a decrease at the BIRC5 promoter in the YM155 treated samples compared to controls.